These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 2779590)

  • 1. Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease.
    Pourcher E; Bonnet AM; Kefalos J; Dubois B; Agid Y
    Mov Disord; 1989; 4(3):195-201. PubMed ID: 2779590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
    Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Variance in effects of subthalamic nucleus stimulation].
    Okiyama R; Yokochi F; Taniguchi M; Takahashi H; Hasegawa N; Hamada I
    No To Shinkei; 2002 Oct; 54(10):883-8. PubMed ID: 12476577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
    Kannari K; Kurahashi K; Tomiyama M; Maeda T; Arai A; Baba M; Suda T; Matsunaga M
    No To Shinkei; 2002 Feb; 54(2):133-7. PubMed ID: 11889759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy.
    Reilly DK; Hershey L; Rivera-Calimlim L; Shoulson I
    Adv Neurol; 1983; 37():51-60. PubMed ID: 6344591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of chronic levodopa therapy in Parkinson's disease.
    Battistin L; Bracco F; Saladini M
    J Neural Transm Suppl; 1986; 22():201-7. PubMed ID: 3465871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Young onset Parkinson's disease.
    Quinn N; Critchley P; Marsden CD
    Mov Disord; 1987; 2(2):73-91. PubMed ID: 3504266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG; Scorticati MC; Micheli FE
    Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
    Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
    Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
    Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoniazid therapy in Parkinson's disease.
    Gershanik OS; Luquin MR; Scipioni O; Obeso JA
    Mov Disord; 1988; 3(2):133-9. PubMed ID: 3221901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum of levodopa-induced dyskinesias.
    Fahn S
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S2-9; discussion S9-11. PubMed ID: 10762127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset.
    Pantelatos A; Fornadi F
    Adv Neurol; 1993; 60():690-7. PubMed ID: 8420212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
    Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
    Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1994; 24(1):12-21. PubMed ID: 8147565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
    LeWitt PA
    Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.